PolyPeptide Group AG (SW:PPGN) — Market Cap & Net Worth
Market Cap & Net Worth: PolyPeptide Group AG (PPGN)
PolyPeptide Group AG (SW:PPGN) has a market capitalization of $810.06 Million (CHF640.74 Million) as of October 9, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #9871 globally and #126 in its home market, demonstrating a -0.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PolyPeptide Group AG's stock price CHF43.90 by its total outstanding shares 32991450 (32.99 Million).
PolyPeptide Group AG Market Cap History: 2021 to 2026
PolyPeptide Group AG's market capitalization history from 2021 to 2026. Data shows change from $5.69 Billion to $1.83 Billion (-6.28% CAGR). Check latest PolyPeptide Group AG stock price today for real-time trading data and today's change.
PolyPeptide Group AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PolyPeptide Group AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see PolyPeptide Group AG cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
3.50x
PolyPeptide Group AG's market cap is 3.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.69 Billion | $282.13 Million | $47.26 Million | 20.18x | 120.50x |
| 2022 | $1.06 Billion | $280.98 Million | $7.77 Million | 3.76x | 135.97x |
| 2023 | $730.76 Million | $320.37 Million | -$51.44 Million | 2.28x | N/A |
| 2024 | $1.18 Billion | $338.69 Million | -$19.56 Million | 3.50x | N/A |
Competitor Companies of PPGN by Market Capitalization
Companies near PolyPeptide Group AG in the global market cap rankings as of October 9, 2026. See how leveraged is PolyPeptide Group AG's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to PolyPeptide Group AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #599 globally with a market cap of $45.58 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #620 globally with a market cap of $44.06 Billion USD ( CN¥301.09 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #599 | GALDERMA GROUP AG | NYSE:GALDY | $45.58 Billion | $39.09 |
| #620 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.06 Billion | CN¥47.20 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.90 |
PolyPeptide Group AG Historical Marketcap From 2021 to 2026
Between 2021 and today, PolyPeptide Group AG's market cap moved from $5.69 Billion to $ 1.83 Billion, with a yearly change of -6.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF1.83 Billion | +68.20% |
| 2025 | CHF1.09 Billion | -8.10% |
| 2024 | CHF1.18 Billion | +62.10% |
| 2023 | CHF730.76 Million | -30.81% |
| 2022 | CHF1.06 Billion | -81.45% |
| 2021 | CHF5.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 8th, 2026 the market cap of PolyPeptide Group AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $810.06 Million USD |
| MoneyControl | $810.06 Million USD |
| MarketWatch | $810.06 Million USD |
| marketcap.company | $810.06 Million USD |
| Reuters | $810.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more